Craig Hallum Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals (NASDAQ:ETON - Free Report) had its price target increased by Craig Hallum from $15.00 to $18.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright raised their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday.

Eton Pharmaceuticals Stock Performance

ETON stock traded up $0.02 during midday trading on Wednesday, reaching $12.01. 322,296 shares of the company's stock traded hands, compared to its average volume of 376,919. The firm has a market capitalization of $312.87 million, a PE ratio of -54.59 and a beta of 1.38. The company has a 50-day moving average price of $11.51 and a two-hundred day moving average price of $7.28. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $15.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth $3,095,000. Wasatch Advisors LP purchased a new position in Eton Pharmaceuticals during the third quarter worth about $1,431,000. Aristides Capital LLC bought a new position in Eton Pharmaceuticals in the 2nd quarter worth about $658,000. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at about $420,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $362,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.